NCoA-3 Antibody (B-3): sc-515530

NCoA-3 Antibody (B-3) is a mouse monoclonal IgG1 antibody that detects NCoA-3 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). NCoA-3, also known as RAC3, ACTR, AIB-1, and p/CIP, plays a crucial role as a transcriptional coactivator in the regulation of gene expression, particularly in hormone-responsive pathways. NCoA-3 is primarily located in the nucleus, where NCoA-3 interacts with various nuclear receptors, including steroid hormone receptors, to modulate transcriptional activity. Nuclear localization of NCoA-3 allows for precise regulation of gene expression in response to hormonal signals, which is essential for processes such as cell growth, differentiation, and metabolism. NCoA-3 has been implicated in the development of estrogen receptor-positive ovarian and breast cancers, highlighting NCoA-3′s importance in cancer biology and potential as a therapeutic target. With NCoA-3′s ability to enhance the transcriptional activity of p300/CBP-dependent transcription factors, NCoA-3 serves as a key player in the intricate network of gene regulation, making anti-NCoA-3 antibody (B-3) an invaluable tool for researchers studying these critical biological processes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

NCoA-3 Antibody (B-3) References:

1. ACTR/AIB1/SRC-3 and androgen receptor control prostate cancer cell proliferation and tumor growth through direct control of cell cycle genes.  |  Zou, JX., et al. 2006. Prostate. 66: 1474-86. PMID: 16921507
2. Essential roles for the nuclear receptor coactivator Ncoa3 in pluripotency.  |  Percharde, M. and Azuara, V. 2013. Cell Cycle. 12: 195-6. PMID: 23287469
3. NCOA3-mediated upregulation of mucin expression via transcriptional and post-translational changes during the development of pancreatic cancer.  |  Kumar, S., et al. 2015. Oncogene. 34: 4879-89. PMID: 25531332
4. NCOA3 coactivator is a transcriptional target of XBP1 and regulates PERK-eIF2α-ATF4 signalling in breast cancer.  |  Gupta, A., et al. 2016. Oncogene. 35: 5860-5871. PMID: 27109102
5. Residual Structure Accelerates Binding of Intrinsically Disordered ACTR by Promoting Efficient Folding upon Encounter.  |  Liu, X., et al. 2019. J Mol Biol. 431: 422-432. PMID: 30528464
6. The inflammatory cytokine TNF contributes with RAC3-induced malignant transformation.  |  Machado, MS., et al. 2018. EXCLI J. 17: 1030-1042. PMID: 30585274
7. Hypomethylated gene RAC3 induces cell proliferation and invasion by increasing FASN expression in endometrial cancer.  |  Meijuan, C., et al. 2022. Int J Biochem Cell Biol. 150: 106274. PMID: 35917927
8. Estrogen-dependent activation of NCOA3 couples with p300 and NF-κB to mediate antiapoptotic genes in ER-positive breast cancer cells.  |  Wang, J. and Zhou, Z. 2023. Discov Oncol. 14: 28. PMID: 36853387
9. USP24-dependent stabilization of Runx2 recruits a p300/NCOA3 complex to transactivate ADAMTS genes and promote degeneration of intervertebral disc in chronic inflammation mice.  |  Li, X., et al. 2023. Biol Direct. 18: 37. PMID: 37415159
10. KLF1 Activates RAC3 to Mediate Fatty Acid Synthesis and Enhance Cisplatin Resistance in Bladder Cancer Cells.  |  Song, L., et al. 2024. Am J Mens Health. 18: 15579883241273305. PMID: 39376007

The preferred NCoA-3 antibody is NCoA-3 Antibody (F-2): sc-5305.